Cytarabine Hydrochloride for Injection

This product is a pyrimidine anti-metabolite drug that mainly acts on cells in the S proliferation phase. It interferes with cell proliferation by inhibiting the synthesis of cell DNA. After entering the human body, cytarabine is phosphorylated by kinase and converted into cytarabine triphosphate and cytarabine diphosphate. The former can strongly inhibit the synthesis of DNA polymerase, and the latter can inhibit the conversion of cytidine diphosphate to deoxycytidine diphosphate, thereby inhibiting cell DNA polymerization and synthesis. This product is a cell cycle-specific drug, which is most sensitive to cells in the S proliferation phase, and has a weaker effect on inhibiting RNA and protein synthesis.

Cytarabine hydrochloride.

This product is white loose mass or powder.

It is suitable for the induction remission and maintenance consolidation phases of acute leukemia. It has a better effect on acute non-lymphocytic leukemia, the blast crisis phase of chronic myeloid leukemia, and malignant lymphoma.

1 Common dosage for adults: (1) Induction of remission: intravenous injection or drip once 2 mg/kg (or 1-3 mg/kg) per body weight, once a day, for 10-14 days. If there is no obvious adverse reaction, the dose can be increased to 4-6 mg/kg per body weight; (2) Maintenance: After complete remission, switch to maintenance treatment dose, once 1 mg/kg per body weight, 1-2 times a day, subcutaneous injection, for 7-10 days. 2 Medium-dose cytarabine Medium-dose refers to a regimen of cytarabine with a dose of 0.5-1.0 g/m2 per body surface area, generally requiring intravenous drip for 1-3 hours, twice a day, with a course of 2-6 days; high-dose cytarabine is a regimen of 1-3 g/m2 per body surface area, with intravenous drip and course of treatment the same as the medium-dose regimen. Since the adverse reactions of cytarabine increase with the increase of dose, sometimes it limits its efficacy, so the medium-dose regimen is now more preferred. Medium or high-dose cytarabine is mainly used to treat refractory or recurrent acute leukemia, and can also be used to prolong the remission period after the remission of acute leukemia. Due to the large number of adverse reactions, the course of treatment must be guided by a doctor with rich experience, and sufficient and timely supportive therapy must be guaranteed before it can be carried out; 3 The dose of low-dose cytarabine is 10 mg/m2 per body surface area, subcutaneous injection, twice a day, with a course of 14 to 21 days. If there is no remission and the patient's condition permits, a course of treatment can be repeated in 2 to 3 weeks. This regimen is mainly used to treat patients with increased primitive cells or myelodysplastic syndrome, and can also treat low-proliferative acute leukemia, senile acute lymphocytic leukemia, etc.; 4 Intrathecal injection of cytarabine is the second-line drug for intrathecal injection to prevent and treat meningeal leukemia, with a dose of 25-75 mg once, combined with dexamethasone 5 mg, dissolved in 2ml 0.9% sodium chloride injection, intrathecal injection, 1-2 times a week, until the cerebrospinal fluid is normal. If it is for prevention, it is once every 4-8 weeks.

1. Hematopoietic system: mainly bone marrow suppression, leukopenia and thrombocytopenia, severe cases may develop aplastic anemia or megaloblastic anemia; 2. Hyperuricemia may occur in patients with leukemia and lymphoma at the beginning of treatment, and uric acid nephropathy may occur in severe cases; 3. Less common symptoms include stomatitis, esophagitis, abnormal liver function, fever reaction and thrombophlebitis. Cytarabine syndrome usually occurs 6 to 12 hours after medication, with symptoms such as bone pain or myalgia, sore throat, fever, general discomfort, rash, and red eyes.

Not suitable for pregnant or lactating women.

Precautions for children: Not clear yet. Precautions for pregnancy and lactation: Pregnant and lactating women should not use. Precautions for the elderly: As the elderly have poor tolerance to chemotherapy drugs, the dosage should be reduced and the dosage should be adjusted in time according to physical signs.

Tetrahydrouridine can inhibit deaminase, prolong the plasma half-life of cytarabine, increase the blood concentration, and play a synergistic role. This product can synchronize cells partially, and continued use of daunorubicin, doxorubicin, cyclophosphamide and nitrosourea drugs can enhance the effect. This product should not be used in combination with 5-Fmu;.

Keep sealed and away from light.

0.1g

24 months

Harbin Laiboten Pharmaceutical Co., Ltd.

• Founded in:

  2010-12-24

• Address:

  No. 13 Beijing Road, Limin Development Zone, Harbin

• Tax NO.:

  91230111565413195T

• Registered Funds:

  85 million yuan

• Email:

  Log in to view